Charles River Laboratories International, Inc. (NYSE:CRL) Shares Sold by Envestnet Portfolio Solutions Inc.

Envestnet Portfolio Solutions Inc. cut its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 35.0% in the first quarter, according to its most recent disclosure with the SEC. The firm owned 4,679 shares of the medical research company's stock after selling 2,524 shares during the period. Envestnet Portfolio Solutions Inc.'s holdings in Charles River Laboratories International were worth $704,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Janney Montgomery Scott LLC raised its position in Charles River Laboratories International by 13.1% during the first quarter. Janney Montgomery Scott LLC now owns 44,500 shares of the medical research company's stock worth $6,698,000 after acquiring an additional 5,148 shares during the period. Smartleaf Asset Management LLC raised its position in Charles River Laboratories International by 61.6% during the fourth quarter. Smartleaf Asset Management LLC now owns 459 shares of the medical research company's stock worth $84,000 after acquiring an additional 175 shares during the period. State of Alaska Department of Revenue raised its position in Charles River Laboratories International by 1.0% during the first quarter. State of Alaska Department of Revenue now owns 15,914 shares of the medical research company's stock worth $2,395,000 after acquiring an additional 150 shares during the period. M.D. Sass LLC raised its position in Charles River Laboratories International by 22.0% during the fourth quarter. M.D. Sass LLC now owns 391,824 shares of the medical research company's stock worth $72,331,000 after acquiring an additional 70,652 shares during the period. Finally, CenterBook Partners LP acquired a new position in Charles River Laboratories International during the fourth quarter worth $4,729,000. 98.91% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 500 shares of the company's stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $145.41, for a total value of $72,705.00. Following the transaction, the executive vice president now owns 19,513 shares of the company's stock, valued at $2,837,385.33. This represents a 2.50% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. 1.30% of the stock is currently owned by corporate insiders.

Charles River Laboratories International Stock Performance

NYSE:CRL opened at $150.24 on Thursday. The company has a debt-to-equity ratio of 0.78, a current ratio of 1.43 and a quick ratio of 1.16. The firm has a market capitalization of $7.38 billion, a price-to-earnings ratio of -231.14, a PEG ratio of 4.58 and a beta of 1.48. The company's 50-day moving average is $134.33 and its two-hundred day moving average is $154.62. Charles River Laboratories International, Inc. has a 1-year low of $91.86 and a 1-year high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last posted its earnings results on Wednesday, May 7th. The medical research company reported $2.34 earnings per share for the quarter, beating the consensus estimate of $2.06 by $0.28. The company had revenue of $984.17 million for the quarter, compared to analyst estimates of $942.34 million. Charles River Laboratories International had a negative net margin of 0.66% and a positive return on equity of 15.19%. Charles River Laboratories International's revenue was down 2.7% on a year-over-year basis. During the same period in the previous year, the business posted $2.27 EPS. Analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Wall Street Analysts Forecast Growth

CRL has been the subject of a number of research analyst reports. TD Cowen upgraded shares of Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a research report on Wednesday, May 14th. The Goldman Sachs Group lowered shares of Charles River Laboratories International from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $190.00 to $170.00 in a report on Friday, March 21st. Citigroup raised shares of Charles River Laboratories International from a "sell" rating to a "neutral" rating and upped their target price for the stock from $155.00 to $175.00 in a report on Tuesday, March 4th. Mizuho dropped their target price on shares of Charles River Laboratories International from $175.00 to $155.00 and set a "neutral" rating for the company in a report on Wednesday, April 9th. Finally, Robert W. Baird upped their target price on shares of Charles River Laboratories International from $118.00 to $140.00 and gave the stock a "neutral" rating in a report on Thursday, May 8th. One equities research analyst has rated the stock with a sell rating, thirteen have assigned a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Charles River Laboratories International has an average rating of "Hold" and an average target price of $171.85.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).

Want to see what other hedge funds are holding CRL? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Charles River Laboratories International, Inc. (NYSE:CRL - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.